| Study Period |
Site |
Criteria for failure |
N |
Median Duration of ART (months) |
ART Regimen (%) |
≥1 DRM
(%) |
NNRTI
(%) |
M184V
(%) |
Any TAM
(%) |
TAM ≥3
(%) |
K65R
(%) |
Ref |
| Dec 2010 – Mar 2012 |
Hlabisa
(17 rural clinics) |
1 × VL >1000 |
222 |
42
|
d4T/3TC/EFV (51) d4T/3TC/NVP (24)
AZT/3TC/EFV (8)
TDF/3TC/EFV (11)
Other (6) |
86.0 |
83.0 |
78.0 |
40.0 |
18.0 |
6.0 |
Manasa et al.
[34] |
| Sep 2010 to Mar 2011 |
Urban clinic |
1 × VL >1000 |
33 |
5.7 |
TDF/3TC/EFV (89) |
>97.0 |
97.0 |
27.3 |
15.2 |
NR |
70.0 |
Sunpath et
al. [33] |
| NR |
Durban
(urban hospital) |
1 × VL >5000 |
43 |
29 |
d4T/3TC/EFV (51)
AZT/3TC/EFV (29) AZT/3TC/NVP (9)
Other (10) |
95.0 |
95.0 |
87.0 |
55.0 |
NR |
NR |
Singh et al.
[32] |
| Aug 2004 to Aug 2006 |
Urban Clinics |
1 × VL >1000 |
141 |
NR |
D4T/3TC/EFV (43)
D4T/3TC/NVP (6)
AZT/3TC/EFV (27)
AZT/3TC/NVP (12)
OTHER (11) |
86.5 |
NR |
NR |
NR |
NR |
5.0 |
Murphy et al.
[31] |
| Jan 2005 – Aug 2006 |
Durban
(two urban hospitals) |
1 × VL >1000 |
115 |
10.8 |
d4T/3TC/EFV (49) d4T/3TC/NVP (5)
AZT/3TC/EFV (26)
AZT/3TC/NVP (11)
Other (8) |
83.5 |
78.3 |
64.3 |
32.2 |
13.0 |
2.6 |
Marconi et al.
[30] |
ART, antiretroviral therapy; N, number of patients genotyped; DRM, drug resistance mutation; TAM, thymidine analogue mutation; VL, viral load; NR, Not reported; NA,
Not applicable; Ref- Reference. |
